ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
🤖 D.R.A.F.T. Summary
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD P
No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 2027 Cambridge, Massachusetts, July 28, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biopharmaceutical company developing therapeutics that selectively target toxic misfolded proteins in neurodegenerative diseases, […]
Outlets covering this story
Toronto Star
CENTER
Financial Post
CENTER
2 of 5 perspectives covered — limited perspective range
Side-by-Side Outlet Comparison — Starter+
See how 2 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →